COMMUNIQUÉS West-GlobeNewswire

HCW Biologics’ Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer
06/11/2026
Designated as one of the Top 150 abstracts submitted for the 41 st Annual Meeting of the Society for Immunotherapy of Cancer HCW11-040 is a first-in-class, second-generation, tetravalent pembrolizumab (Keytruda®) based [...]
Chemed Corporation Declares Quarterly Dividend of 70 Cents
06/11/2026
CINCINNATI, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE ) announced today that the Board of Directors has declared a quarterly cash dividend of 70-cents per share on the Company’s capital stock, [...]
Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
06/11/2026
Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, France 06 novembre 2026 (17h45 CEST) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ) , la Speciality Pharma qui [...]
Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
06/11/2026
Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, France 06 novembre 2026 (17h45 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ) , la Speciality Pharma qui [...]
Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma
06/11/2026
In 17 first-line patients treated with the combination, the estimated two-year overall survival (OS) rate was 70% - Median OS was not reached at a median follow-up of 29 months and 10 patients remained on study Majority [...]
Ipsen - Octobre 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
06/11/2026
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
Ipsen - October 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
06/11/2026
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
Spectral Medical Inc. Announces Closing of Second Tranche of $14.0 Million Convertible Note Private Placement
06/11/2026
TORONTO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“ Spectral ” or the “ Company ”) (TSX: EDT), a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic [...]
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]
MIMEDX to Participate in Upcoming Investor Conferences
06/11/2026
MARIETTA, Ga., Nov. 06, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences [...]
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates
06/11/2026
PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk and high-grade Ta NMIBC anticipated November 2026 BOND-003 Cohort P and CORE-008 Cohort CX 12-month data [...]
Notification of managers’ transactions
06/11/2026
ANNOUNCEMENT NO. 327 6 November 2026 ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation No. 596/2014 concerning transactions in shares of ChemoMetec A/S carried out by persons [...]
OneMedNet Reports Preliminary Revenue for Third Quarter 2026 and Fourth Quarter 2026 Outlook
06/11/2026
MINNEAPOLIS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI [...]
BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application
06/11/2026
SUNNYVALE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ: BCDA) , a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today [...]
Quoin Pharmaceuticals’ Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome
06/11/2026
Kristi and Kodi Share Their Experience Living with the Rare Genetic Skin Disease, Alongside Insights from Pediatric Dermatologist Moise Levy, MD Kodi, who lives with Netherton Syndrome, in the latest NETHERTON NOW [...]
CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
06/11/2026
PARSIPPANY, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the third quarter ended September 30, 2026, before the market opens [...]
ICU Medical to Present at the 2026 Jefferies Global Healthcare Conference in London
06/11/2026
SAN CLEMENTE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will [...]
Azalea Therapeutics Presents New Preclinical Data at SITC 2026 Highlighting Durable Anti-Tumor Activity and Modular Capabilities of its In Vivo CAR T Cell Platform
06/11/2026
In vivo-engineered TRAC-CAR T cells demonstrate complete leukemia tumor clearance in mice, including following tumor rechallenge without additional dosing Modular platform enables dual-antigen targeting to limit tumor [...]
Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026
06/11/2026
- Durable complete regressions observed in 50% of mice in a RAS-mutant colorectal cancer model treated with Atebimetinib plus anti-PD-1, with no regrowth even after dosing stopped - - Median survival extended by 1.8- [...]

Pages